Integrating pharmacogenomics into the electronic health record by implementing genomic indicators

Pharmacogenomics (PGx) clinical decision support integrated into the electronic health record (EHR) has the potential to provide relevant knowledge to clinicians to enable individualized care. However, past experience implementing PGx clinical decision support into multiple EHR platforms has identified important clinical, procedural, and technical challenges. Commercial EHRs have been widely criticized for the lack of readiness to implement precision medicine. Herein, we share our experiences and lessons learned implementing new EHR functionality charting PGx phenotypes in a unique repository, genomic indicators, instead of using the problem or allergy list. The Gen-Ind has additional features including a brief description of the clinical impact, a hyperlink to the original laboratory report, and links to additional educational resources. The automatic generation of genomic indicators from interfaced PGx test results facilitates implementation and long-term maintenance of PGx data in the EHR and can be used as criteria for synchronous and asynchronous CDS.

[1]  Gianrico Farrugia,et al.  Multidisciplinary Model to Implement Pharmacogenomics at the Point of Care , 2016, Genetics in Medicine.

[2]  Keith Marsolo,et al.  Empowering genomic medicine by establishing critical sequencing result data flows: the eMERGE example , 2018, J. Am. Medical Informatics Assoc..

[3]  Janet E Olson,et al.  Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality. , 2016, The American journal of medicine.

[4]  R. Weinshilboum,et al.  Pharmacogenetics and pharmacogenomics: development, science, and translation. , 2006, Annual review of genomics and human genetics.

[5]  Dan M. Roden,et al.  Leveraging the electronic health record to implement genomic medicine , 2012, Genetics in Medicine.

[6]  William E. Evans,et al.  Pharmacogenomics in the clinic , 2015, Nature.

[7]  Casey Lynnette Overby,et al.  Implementation of pharmacogenetics: The University of Maryland personalized anti‐platelet pharmacogenetics program , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[8]  E. Clayton,et al.  Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project , 2012, Clinical pharmacology and therapeutics.

[9]  Charis Eng,et al.  Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services , 2016, Pharmacotherapy.

[10]  N J Cox,et al.  The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics , 2012, Clinical pharmacology and therapeutics.

[11]  Kevin B. Johnson,et al.  Electronic health record design and implementation for pharmacogenomics: a local perspective , 2013, Genetics in Medicine.

[12]  Ching-Hon Pui,et al.  PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogenetics , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[13]  Teri E Klein,et al.  Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. , 2015, Annual review of pharmacology and toxicology.

[14]  Jennifer B. McCormick,et al.  Genomic Data in the Electronic Medical Record , 2014, Journal of empirical research on human research ethics : JERHRE.

[15]  Jeffrey C. Hall,et al.  The CLIPMERGE PGx Program: Clinical Implementation of Personalized Medicine Through Electronic Health Records and Genomics–Pharmacogenomics , 2013, Clinical pharmacology and therapeutics.

[16]  M. Relling,et al.  Development and use of active clinical decision support for preemptive pharmacogenomics , 2013, Journal of the American Medical Informatics Association : JAMIA.

[17]  Meghan J. Arwood,et al.  Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges , 2016, Clinical and translational science.

[18]  Julie A Johnson,et al.  Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. , 2013, Pharmacogenomics.

[20]  Christopher G Chute,et al.  Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. , 2014, Mayo Clinic proceedings.

[21]  D. Roden,et al.  The Emerging Role of Electronic Medical Records in Pharmacogenomics , 2011, Clinical pharmacology and therapeutics.

[22]  S. Scott,et al.  Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology. , 2018, The Journal of molecular diagnostics : JMD.

[23]  PJ Caraballo,et al.  Electronic Medical Record‐Integrated Pharmacogenomics and Related Clinical Decision Support Concepts , 2017, Clinical pharmacology and therapeutics.

[24]  D M Roden,et al.  Electronic Medical Records as a Tool in Clinical Pharmacology: Opportunities and Challenges , 2012, Clinical pharmacology and therapeutics.

[25]  M. A. Hoffman,et al.  The genome-enabled electronic medical record , 2007, J. Biomed. Informatics.

[26]  David C. Kochan,et al.  The Return of Actionable Variants Empirical (RAVE) Study, a Mayo Clinic Genomic Medicine Implementation Study: Design and Initial Results , 2018, Mayo Clinic proceedings.

[27]  T. Klein,et al.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.

[28]  M. Whirl‐Carrillo,et al.  Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists. , 2019, The Journal of molecular diagnostics : JMD.

[29]  Amnon Shabo,et al.  Clinical genomics data standards for pharmacogenetics and pharmacogenomics. , 2006, Pharmacogenomics.